From the clinic to the bench, and back.
Pancreatic cancer rarely gives second chances. We make the first one count — turning each patient's tumour into a living model that points to the treatment most likely to work, fast enough to matter.
One step closer to personalized pancreatic-cancer care
Three ways we translate
Patient-derived organoids
Growing organoids from tumour biopsies and testing them against the drugs a patient might receive — asking whether organoid response predicts what happens in the clinic, fast enough to inform real decisions.
Liquid biopsy & ctDNA
Blood-based assays for earlier detection in high-risk groups and for tracking minimal residual disease after surgery, validated against longitudinal patient cohorts.
Biomarker-guided trials
Randomized and ctDNA-guided trials that put molecular markers to the test at the point of care — assigning therapy by what the tumour is actually doing.
Open to patients
Biomarker-Stratified First-Line Therapy in Metastatic Pancreatic Cancer: A Randomized Trial
Metastatic pancreatic ductal adenocarcinoma
ctDNA-Guided Adjuvant Therapy After Pancreatic Cancer Resection
Resected pancreatic ductal adenocarcinoma with detectable minimal residual disease